Long-term adherence to treatment in patients with ischemic heart disease and myocardial infarction in comparison with other cardiovascular diseases


DOI: https://dx.doi.org/10.18565/therapy.2019.1.54-59

Pereverzeva K.G., Loukianov M.M., Martsevich S.Yu., Andreenko E.Yu., Zagrebelnyy A.V., Boytsov S.A., Yakushin S.S.

1 ФГБОУ ВО «Рязанский государственный медицинский университет» Минздрава России; 2 ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России; 3 ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России
The aim was to assess and compare the dynamics of adherence to drug therapy in patients included in the register RECVASA during 24–48 months follow-up. Material and methods. The data of 1907 patients with various cardiovascular diseases (CVD) were analyzed, information about their adherence to treatment and their vital status was evaluated 24, 36 and 48 months after inclusion. Results. The data obtained make it evident that adherence to treatment is insufficient, and the adverse course of CVD does not contribute to its increase. In most cases, adherence to treatment changed within 48 months in a wave-like manner. At the same time, the number of patients with ischemic heart disease who were not sufficiently committed to treatment increased from 62,1 to 69,1%, and those highly committed to treatment decreased from 31,9 to 26,3%. The number of non-adherent patients with any CVD decreased from 8,9 to 6,7%.
Keywords: Morisky-Green questionnaire, register, adherence to treatment, coronary artery disease
Read entire article

Literature


  1. Бойцов С.А., Погосова Н.В., Бубнова М.Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 23(6): 7– 122.

  2. Peterson, Eric D., Roe, Matthew T., Mulgund, Jyotsna, DeLong, Elizabeth R., Lytle, Barbara L., Brindis, Ralph G., Smith,Sidney C., Pollack, Charles V., Newby, Kristin L., Harrington, Robert A., Gibler, W. Brian, Ohman, E. Magnus. Association between hospital process performance and outcomes among patients with acute coronary syndromes. Journal of the American Medical Association 2006; 295(16): 1912– 20.

  3. Nguyen T., Le K.K., Cao H.T.K., Tran D.T.T., Ho L.M., Thai T.N.D., Pham H.T.K., Pham P.T., Nguyen T.H., Hak E., Pham T.T.,Taxis K. Association between in-hospital guideline adherence and postdischarge major adverse outcomes of patients with acute coronary syndrome in Vietnam: a prospective cohort study. BMJ Open. 2017; 7(10): e017008.

  4. Dores H., Aguiar C., Ferreira J., Mimoso J., Monteiro S., Seixo F., Santos J.F. On behalf of Portuguese Registry on Acute Coronary Syndromes (ProACS) Investigators. Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomes. Cardiovasc Diagn Ther 2014; 4(1): 13–20.

  5. Paul W. Armstrong, Finlay A. McAlister searching for adherence can we fulfill the promise of evidence-based medicines? Journal of the American College of Cardiology 2016; 68(8): 802–04.

  6. Stewart A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster – randomized, controlled trial (HAPPy trial). J Clin Pharm Ther. 2014; 39 (5): 527–34.

  7. Cramer J., Amonkar M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research and Opinions 2005; 2 (9): 1453–60.

  8. Cowell W., Fulford-Smith A., Poultney S. Adherence lath awake to bisphosphonate running all for osteoporosis inwardly UK patients. Bone. 2005; 36(2): 409–10.

  9. Carter S., Taylor D., Levenson R. A question of choice – compliance in medicine taking: A preliminary review. 3rd Ed. London: Medicines Partnership, 2005: 101.

  10. Osterberg L., Blaschke T.N. Adherence to medication. Engl J Med. 2005; 353: 487–89.

  11. Бойцов С.А., Якушин С.С., Марцевич С.Ю. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. Рациональная фармакотерапия в кардиологии. 2013; 9(1): 4–14.

  12. Лукьянов М.М., Козминский А.Н., Марцевич С.Ю. и др. Больные с сочетанием хронической сердечной недостаточности, артериальной гипертонии и перенесенного ранее инфаркта миокарда: клинико-анамнестические характеристики и практика назначения ингибиторов ангиотензинпревращающего фермента, блокаторов рецепторов ангиотензина и β-адреноблокаторов, приверженность лечению (данные амбулаторного регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2017; 13(2): 207–12.

  13. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1): 67–74.

  14. Нелидова А.В., Усачева Е.В., Замахина О.В., Супрун Е.В. Факторы, влияющие на приверженность к лечению у пациентов с коронарным атеросклерозом в отдаленном периоде сосудистого события. Современные проблемы науки и образования. 2015; 4: 364.

  15. Целуйко В.И., Яковлева Л.Н., Строкова С.А. Влияние приверженности к лечению на прогноз у больных, перенесших инфаркт миокарда. Лики Украины 2012; 1(2): 40–43.


About the Autors

Kristina G. Pereverzeva, PhD, assistant of the Department of hospital therapy, Federal State budgetary educational institution of high education «Ryazan State medical University named after Academician I.P. Pavlov» of the Ministry of Health of the Russian Federation. Address: 390026, Ryazan, 9 Vysokovoltnaya str. E-mail: pereverzevakg@gmail.com
Sergey A. Boytsov, MD, professor, corresponding member of the Russian Academy of sciences, general director of Federal State budgetary institution «National medical research Center for cardiology» of the Ministry of Health of the Russian Federation. Address: 101990 Moscow, 15a Tretya Cherepkovskaya. E-mail: prof.boytsov@gmail.com
Mikhail M. Loukianov, PhD, head of the Department of clinical cardiology and molecular genetics, Federal State budgetary institution «National medical research Center for preventive medicine» of the Ministry of Health of the Russian Federation. Address: 101990 Moscow, 10 Petroverigsky lane. E-mail: loukmed@gmail.com
Sergey Yu. Martsevich, MD, professor, head of the Department of preventive pharmacotherapy, Federal State budgetary institution «National medical research Center for preventive medicine» of the Ministry of Health of the Russian Federation. Address: 101990 Moscow, 10 Petroverigsky lane. E-mail: SMartsevich@gnicpm.ru
Alexander V. Zagrebelnyy, PhD, senior researcher of the Department of preventive pharmacotherapy, Federal State budgetary institution «National medical research Center for preventive medicine» of the Ministry of Health of the Russian Federation. Address: 101990 Moscow, 10 Petroverigsky lane. E-mail: AZagrebelny@gnicpm.ru
Elena Yu. Andreenko, PhD, senior researcher, Department of clinical cardiology and molecular genetics, Federal State budgetary institution «National medical research Center for preventive medicine» of the Ministry of Health of the Russian Federation. Address: 101990 Moscow, 10 Petroverigsky lane. E-mail: EAndreenko@gnicpm.ru
Sergey S. Yakushin, MD, Ph.D., professor, head of the Department of hospital therapy, Federal State budgetary educational institution of high education «Ryazan State medical University named after Academician I.P. Pavlov» of the Ministry of Health of the Russian Federation. Address: 390026 Ryazan, Vysokovoltnaya ul. 9. E-mail: prof.yakushin@gmail.com


Similar Articles

Back to Content

Бионика Медиа